期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人乳腺癌细胞MCF-7/HER2稳转株裸鼠移植瘤模型的建立 被引量：5

Establishment of nude mice xenograft model of human breast cancer cell strain MCF-7 /HER2 with stable-transfected HER2
暂未订购
导出
摘要 HER2受体属于表皮生长因子受体（epidermal growth factor receptor,EGFR）家族,在乳腺癌、胃癌与卵巢癌等恶性肿瘤中的过表达往往预示肿瘤易发生转移及预后不良[1]。本实验室在国内较早开展抗HER2治疗性抗体研发工作,相继制备有鼠源性单克隆抗体A21及人源化抗体chA21等[2-4],为了评价这类针对HER2受体的靶向治疗药物的药理作用,本研究采用HER2表达质粒稳定转染人乳腺癌细胞MCF-7,经筛选获得HER2过表达的MCF-7/HER2细胞株,
作者 沈国栋 杜锐凯 査昭 胡思怡 王弦 吴强 胡世莲 刘兢
机构地区 安徽医科大学附属省立医院老年医学科 中国科学技术大学生命科学学院 安徽医科大学第二附属医院病理科
出处 《中国药理学通报》 CAS CSCD 北大核心 2013年第4期588-589,共2页 Chinese Pharmacological Bulletin
基金 国家重大科技专项资助项目(No 2009ZX09102-223) 安徽省自然科学基金资助项目(No 090413125) 安徽高校省级自然科学研究重点项目(No KJ2012A284)
关键词 乳腺癌 HER2 ERBB2 MCF-7 靶向治疗 裸鼠 动物模型 breast cancer HER2/ErbB2 MCF-7 targeted therapy nude mice animal model
分类号 R-332 [医药卫生] R363-332 [医药卫生—病理学]
  • 相关文献

参考文献3

二级参考文献20

  • 1刘伦华,楼丽广.PTEN功能调节的研究进展[J].中国药理学通报,2005,21(7):778-781. 被引量：16
  • 2Burstein H J.The distinctive nature of HER2-positive breast cancers[J].N Engl J Med,2005,353(16):1652-4.
  • 3Wainberg Z A,Anghel A,Desai A J,et al.Lapatinib,a dual EGFR and HER2 kinase inhibitor,selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo[J].Clin Cancer Res,2005,16(5):1509-19.
  • 4Hu S,Zhu Z,Li L,et al.Epitope mapping and structural analysis of an anti-ErbB2 antibody A21:Molecular basis for tumor inhibitory mechanism[J].Proteins,2008,70(3):938-49.
  • 5Polcher M,Rudlowski C,Friedrichs N,et al.In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer[J].BMC Cancer,2010(10):137.
  • 6Campling B G,Haworth A C,Baker H M,et al.Establishment and characterization of a panel of human lung cancer cell lines[J].Cancer,1992,69(8):2064-74.
  • 7van Slooten H J,Bonsing B A,Hiller A J,et al.Outgrowth of BT-474 human breast cancer cells in immune-deficient mice:a new in vivo model for hormone-dependent breast cancer[J].Br J Cancer,1995,72(1):22-30.
  • 8Ooi S M,Vivian J B,Cohen R J.The use of the Ki-67 marker in the pathological diagnosis of the epithelioid variant of renal angiomyolipoma[J].Int Urol Nephrol,2009,41(3):559-65.
  • 9Laakkonen P,Waltari M,Holopainen T,et al.Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth[J].Cancer Res,2007,67(2):593-9.
  • 10Koukourakis M I,Manolas C,Minopoulos G,et al.Angiogenesis relates to estrogen receptor negativity,c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast[J].Int J Surg Pathol,2003,11(1):29-34.

共引文献11

同被引文献33

  • 1Gutierrez C, Schiff R.HER2: biology, detection, and clinical implications[J].Arch Pathol Lab Med, 2011,135(1):55-62.
  • 2Noordhuis M G, Eijsink J J, Roossink F, et al.Prognostic cell biological markers in cervical cancer patients primarily treated with(chemo) radiation: a systematic review[J].Int J Radiat Oncol Biol Phys, 2011,79(2):325-34.
  • 3Rodriguez G F, Sieuwerts A M, Smid M, et al.MicroRNA 30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer[J].Breast Cancer Res Treat, 2011,127(1):43-51.
  • 4Adachi R, Horiuchi S, Sakurazawa Y, et al.ErbB2 down-regulates microRNA205 in breast cancer[J].Biochen Biophys Res Commum, 2011,411(4):804-8.
  • 5Le X F, Almeida M I, Mao W, et al.Modulation of MicroRNA-194 and cell migration by HER-2-targeting trastuzumab in breast cancer[J].PLoS One, 2012,7(7):e41170.
  • 6Fang C, Zhao Y, Guo B.MiR-199b-5p targets HER2 in breast cancer cells[J].J Cell Biochem, 2013,114(7):1457-63.
  • 7Epis M R, Barker A, Giles K M, et al.The RNA-binding protein huR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostat cancer cells[J].J Biol Chem, 2011,286(48):41442-54.
  • 8Jin L, Wessely O, Marcusson E G, et al.Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNFα in breast cancer[J].Cancer Res, 2013,73(9):2884-96.
  • 9Shang C, Lu Y M, Meng L R.MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2[J].Med Sci Monit, 2012,18(4):149-55.
  • 10Chandarlapaty S, Sakr R A, Giri D, et al.Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer[J].Clin Cancer Res, 2012,18(24):6784-91.

引证文献5

二级引证文献6

中国药理学通报
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部